The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas
Authors Harat M, Blok M, Harat A, Soszyńska K
Received 8 January 2019
Accepted for publication 21 February 2019
Published 26 March 2019 Volume 2019:12 Pages 2215—2224
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Takuya Aoki
Maciej Harat,1,2 Maciej Blok,2 Aleksandra Harat,3 Krystyna Soszyńska4
1Department of Oncology and Brachytherapy, Nicolaus Copernicus University, Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland; 2Unit of Radiosurgery and Radiotherapy of CNS, Department of Radiotherapy, Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland; 3Department of Public Health, Nicolaus Copernicus University, Ludwik Rydygier Collegium Medicum, Bydgoszcz, Poland; 4Department of Pathology, Laboratory of Clinical Genetics and Molecular Pathology, 10th Military Hospital, Bydgoszcz, Poland
Purpose: Changes in MGMT promoter methylation, IDH1 and IDH2 mutation, and 1p/19q co-deletion status in gliomas between first and subsequent resections and their associated clinical factors are poorly described. In this study, we assayed these biomarkers in the clinical setting.
Patients and methods: We used multiplex ligation-dependent probe amplification to measure MGMT promoter methylation, IDH mutation status, and 1p/19q co-deletion in 45 paired tumor samples from patients undergoing resection and subsequent re-resections for gliomas.
Results: Molecular changes were present in 20 patients (44%). At least one molecular characteristic changed over time in 89% of patients with primary grade III tumors. Gliomas with IDH wild-type and/or non-co-deleted were stable, but IDH1/2 mutation and/or co-deletion were sometimes lost at the time of recurrence. In a multivariate analysis, adjuvant radiotherapy alone was independently associated (P=0.02) with changes in molecular profile.
Conclusion: Molecular biomarkers change in gliomas during the course of the disease, most often MGMT methylation status. These changes in genetic profiles are related to adjuvant treatment with radiotherapy alone, which might be important for individualized treatment planning over the disease course.
Keywords: glioma, IDH, MGMT, 1p/19q, mutation changes, glioblastoma, anaplastic astrocytoma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]